The clinical and economic potential of cyclosporin drug interactions

PharmacoEconomics

Volumn 15, Issue 4, 1999, Pages 317-337

  Martin, Jill E ^a   Daoud, A Jamal ^a   Schroeder, Timothy J ^a,b,c   First, M Roy ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NICARDIPINE; VERAPAMIL;

CHRONOTHERAPY; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFECT; DRUG MONITORING; DRUG POTENTIATION; ECONOMIC EVALUATION; FRUIT JUICE; GRAPE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TRANSPLANTATION;

CYCLOSPORINE; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0032900516     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915040-00001     Document Type: Review

References (128)

1. 1. Borel JF, Feuer C, Gubler HU, et al. Biological effects of cyclosporine A: a new untilymphocyte agent. Agents Actions 1976; 6 (4): 432-40
2. 2. Borel JF. Comparative study of in vitro and in vivo drug effects on cell mediated cytotoxicity. Immunology 1976; 31: 631-41
3. 3. Calne RY, Rolles K, While DJG, et al. Cyclosporine A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 33 kidneys, 2 pancreases and 2 livers. Lancet 1979; 11: 1033-6
4. 4. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation: one-year follow-up of a multicenter trial. Lancet 1983; 11: 986-9
5. 5. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis al three years. N Engl J Med 1986; 314: 1219-25
6. 6. Stiller CR, Dupre J, Gent M, et al. Sandimmune (cyclosporine) in insulin-dependent diabetes mellitus (type I) of recent onset. Science 1984; 223: 1362-7
7. 7. Nussenblatt RB, Palestine AG, Rook AH, et al. Cyclosporine therapy for intraocular inflammatory disease. Lancet 1983; 11: 235-8
8. 8. Masuda K, Nakajima A. A double-masked study of cyclosporin treatment in Behcet's disease. In: Schinder R, editor. Ciclosporine in autoimmune diseases. Berlin: Springer-Verlag, 1985: 162-4
9. 9. Hunsicker LG. Impact of cyclosporine on cadaveric renal transplantation: a summary statement. Am J Kidney Dis 1985; 5: 335-41
10. 10. Macoviak JA, Oyer PE, Stinson EB, et al. Four-year experience with cyclosporine for heart and heart-lung transplantation. Transplant Proc 1985; 17 Suppl. 2: 97-8
11. 11. Morris PE. The immunology of rejection. In: Morris PJ, editor. Kidney transplantation: principles and practice. 3rd ed. Orlando (FL): Grune & Stratum. 1988: 15-32
12. 12. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Transplant Proc 1988; 20 (3 Suppl. 3): 73-7
13. 13. Kramer NC, Peters TG, Rohr MS, et al. Beneficial effect of cyclosporine on renal transplantation. Transplantation 1990; 49: 343-8
14. 14. Starzl TE, Demetris AJ, Van Thiel D. Medical progress: liver transplantation. N Engl J Med 1989; 321: 1014-22
15. 15. Hall BM, Tiller DJ, Hardic I, et al. Comparison of three immunosuppressive regimens in cadaveric renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988; 318: 1499-507
16. 16. Viste A, Moudry-Mounns K, Sutherland DER. Prognostic risk factors for graft failure following pancreas transplantation: results of multivariate analysis of data from the International Pancreas Transplant Registry. Transpl Int 1990; 3: 98-102
17. 17. Evans RW, Manninen DL. Economic impact of cyclosporine in transplantation. Transplant Proc 1988; 20 Suppl. 3: 49-62
18. 18. Eggers PW. The effect of cyclosporine on the use of hospital resources for kidney transplantation. N Engl J Med 1990; 322: 1010-1
19. 19. Barclay PG, Allen RDM, Stewart JH, et al. Costs of immunosuppressive therapies used in renal transplantation. Transplant Proc 1992; 24: 165-6
20. 20. Areosty J, Rettig RA. The cost effects of improved kidney transplantation. Santa Monica (CA): RAND, 1984. Publication no.: R-3099-NIH/RC
21. 21. Simon DG. A cost-effectiveness analysis of cyclosporine in cadaveric kidney transplantation. Med Decis Making 1986; 6: 199-207
22. 22. Krakauer H. Assessment of alternative technologies for the treatment of end-stage renal disease. Isr J Med Sci 1986; 22: 245-59
23. 23. Henry ML, Sommer BG, Ferguson RM. Beneficial effects of cyclosporine compared with azathioprine in cadaveric renal transplantation. Am J Surg 1985; 150: 533-6
24. 24. Showstack J, Katz P, Amend W, et al. The effect of cyclosporine on the use of hospital resources for kidney transplantation. N Engl J Med 1989; 321: 1086-92
25. 25. Showstack J, Katz P, Amend W, et al. The association of cyclosporine with the one-year costs of cadaver-donor kidney transplants. JAMA 1990; 264: 1818-23
26. 26. Tilney NL, Strom TB, Kupiec-Weglinski JW. Pharmacologic and immunologic agonists and antagonists of cyclosporine. Transplant Proc 1988; 20 Suppl. 3: 13-22
27. 27. Yee GC, Rosano T, Ptachinski R. Pharmacology: profiles, parameters, interpretations and drug interactions. Transplant Proc 1988; 20 Suppl. 2: 715-21
28. 28. Como JA, Dismukes WE. Oral azoles drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-8
29. 29. Markin S. Stratta RJ, Woods GL. Infection after liver transplantation. Am J Surg Pathol 1990; 14 Suppl. 1: 64-71
30. 30. First MR, Schroeder TJ, Weiskittel P, et al. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 1989; 11: 1198-201
31. 31. First MR, Schroeder TJ, Weiskittel P, et al. Cyclosporine-ketoconazole interaction. Transplantation 1993; 55: 1000-4
32. th Annual Meeting, American Society of Transplant Physicians; 1997 May 11-14, Dallas
33. 33. Odocha O, Kelly B, Trimble S, et al. Cost-containment strategies in transplantation: the utility of cyclosporine-ketoconazole combination therapy. Transplant Proc 1996; 28: 907-9
34. 34. Sobh M, El-Agroudy A, Moustafa F, et al. Coadministration of ketoconazole to cyclosporin-treated kidney transplant recipients: a prospective randomized study. Am J Nephrol 1995; 15: 493-9
35. 35. Patton PR, Brunson ME, Pfaff WW, et al. A preliminary report of diltiazem and ketoconazole: their cyclosporine-sparing effect and impact on transplant outcome. Transplantation 1994; 57: 889-92
36. 36. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333: 628-33
37. 37. Butman SM, Wild JC, Nolan PE, et al. Prospective study of the safety and financial, benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J Heart Lung Transplant 1991; 10: 351-8
38. 38. Sergent WK, Martin JE, Schroeder TJ, et al. Pharmacokinetics of the interaction between itraconazole oral solution and cyclosporine in stable post-liver transplant recipients [abstract]. The American Society of Health System Pharmacists Midyear Clinical Meeting; 1998 Dec, Las Vegas
39. th Annual Meeting of the American Society of Transplant Physicians; 1995 May 14-17, Chicago
40. 40. Loose DS, Kan PB, Hirst MA, et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P-450 dependent enzymes. J Clin Invest 1983; 71: 1495-9
41. 41. Meredith CG, Maldonado AL, Speeg KV. The effect of ketoconazole on hepatic oxidative drug metabolism in the rat in vivo and in vitro. Drug Metab Dispos 1985; 13: 156-62
42. 42. Ferguson RM, Sutherland DER, Summons RL, et al. Ketoconazole, cyclosporine metabolism and renal transplantation. Lancet 1982; 11: 882-3
43. 43. Schroedcr TJ, Melvin DB, Clardy CW, et al. The use of cyclosporine and ketoconazole without nephrotoxicity in two cardiac transplant recipients. J Heart Lung Transplant 1987; 6: 84-9
44. 44. Gandhi BV, Kale S, Bhowmik DM, et al. Concomitant administration of cyclosporine and ketoconazole in renal transplant patients. Transplant Proc 1992; 24: 1715
45. 45. Canafax DM, Graves NM, Hilligoss DM, et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51: 1014-8
46. 46. Lopez-Gil JA. Fluconazole cyclosporine interaction: a dose-dependent effect? Ann Pharmacother 1993; 27: 427-30
47. 47. Sugar AM, Saunders C, Idelsan BA, et al. Interaction of fluconazole and cyclosporine [letter]. Ann Intern Med 1989; 110: 844
48. 48. Pfizer, Inc. Fluconazole product information insert. Groton (CT): Pfizer, Inc., 1990
49. 49. Kruger HU, Schuler U, Zimmermann R, et al. Absence of significant interaction of fluconazole with cyclosporin. J Antimicrob Chemother 1989; 24: 781-6
50. 50. Canafax DM, Graves NM, Hilligoss DM, et al. Increased cyclosporine levels as a result of simultaneous fluconazole and cyclosporine therapy in renal transplant recipients: a double-blind, randomized pharmacokinetic and safety study. Transplant Proc 1991; 23: 1041-2
51. 51. Jackson CA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994; 330: 263-72
52. 52. Novakova I, Donnelly P, DeWitte T, et al. Itraconazole and cyclosporine nephrotoxicity. Lancet 1987; 11: 920-1
53. 53. Shaw MA, Gumbleton M, Nicholls PJ. Interaction of cyclosporine and itraconazole [letter]. Lancet 1987; 11: 637
54. 54. Lavrijsen K, Van Houdt J, Thijs D, et al. Interaction of miconazole, ketoconazole and itraconazole with rat-liver microsomes. Xenobiotica 1987; 17: 45-57
55. 55. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113: 327-9
56. 56. Kwan JT, Foxall PJ, Davidson DG, et al. Interaction of cyclosporine and itraconazole [letter]. Lancet 1987; 11: 282
57. 57. Trenk D, Brett W, Jahnchen E, et al. Time course of cyclosporine-itraconazole interaction. Lancet 1987; 11: 1335-6
58. 58. Luke RG. Pathophysiology and treatment of post-transplant hypertension. J Am Soc Nephrol 1991; 2 Suppl. 1: S37-44
59. 59. Cheigh JS, Stenzel KHS, Wang J. Hypertension is associated with dccreaed graft survival in long-term kidney transplant recipients. Transplant Proc 1985; 17: 174-5
60. 60. Murray BM, Paller MS. Beneficial effects of renal denervation and prazosin on GFR and renal blood flow after cyclosporine in rats. Clin Nephrol 1986; 25: 537-9
61. 61. Xue H, Bukoski RD, McCarron DA, et al. Induction of contraction in isolated rat aorta by cyclosporine. Transplantation 1987; 43: 715-8
62. 62. Jao S, Waltzer W, Arbeit LA. Acute cyclosporine induced decrease in GFR is mediated by changes in renal blood flow and renal vascular resistance [abstract]. Kidney Int 1986; 29: 431
63. 63. Kawaguchi A, Goldman MN, Shapiro R, et al. Increase in urinary thromboxane B2 in rats caused by cyclosporine. Transplantation 1985; 40: 214-8
64. 64. Kon V, Sugiuza M, Inagami T, et al. Cyclosporine causes endothelin-dependent acute renal failure [abstract]. Kidney Int 1990; 37: 486
65. 65. Landmann J, Mihatsch MJ, Ratschek M, et al. Cyclosporine A and intravascular coagulation. Transplant Proc 1987; 19: 1817-9
66. 66. Smith C, Hampton EM, Pederson JA, et al. Clinical and medicoeconomic impact of the cyclosporine-diltiazem interaction in renal transplant recipients. Pharmacotherapy 1994; 14: 471-81
67. 67. Valantine H, Keogh A, McIntosh N, et al. Cost containment: coadministration of diltiazem with cyclosporine after heart transplantation. J Heart Lung Transplant 1992; 11: 1-7
68. 68. Pirsch JD, D'Alessandro AM, Roecker EB, et al. A controlled, double-blind, randomized trial of verapamil and cyclosporine in cadaver renal tranplant patients. Am J Kidney Dis 1993; 2: 189-95
69. 69. Chan C, Maurer J, Cardella C, et al. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997; 63: 1435-40
70. 70. McCauley J, Ptachcinski RJ, Shapiro R. The cyclosporine-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989; 21: 3955-7
71. 71. Chrysostomou A, Walker RG, Russ GR, et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993; 55: 300-4
72. 72. Al Edreesi M, Caille G, Dupuis C, et al. Safely, tolerability, and pharmacokinetic actions of diltiazem in pediatric liver transplant recipients on cyclosporine. Liver Transplant Surg 1995; 1: 383-8
73. 73. MacDonald P, Keogh A, Connell J, et al. Diltiazem co-administration reduces cyclosporine toxicity after heart transplantation: A prospective randomized trial. Transplant Proc 1992; 24: 2159-62
74. 74. Kiowski W, Linder L, Buhler FR. Arterial vasodilator and antihypertensive effects of diltiazem. J Cardiovasc Pharmacol 1990; 16 Suppl. 6: S7-10
75. 75. Hung J, Hackett PL, Gordon SPF, et al. Pharmacokinetics of diltiazem in patients with unstable angina pectoris. Clin Pharmacol Ther 1988; 43: 466-70
76. 76. Pochet JM, Pirson Y. Cyclosporin-diltiazem interaction [letter]. Lancet 1986; 1: 979
77. 77. Grino JM, Sabate I, Castelao AM, et al. Influence of diltiazem on cyclosporine clearance [letter]. Lancet 1986; 1: 1387
78. 78. Renton KW. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem Pharmacol 1985; 34: 2549-53
79. 79. Bourge RC, Kirklin JK, Naftel DC, et al. Diltiazem-cyclosporine interaction in cardiac transplant recipients; impact on cyclosporine dose and medication costs. Am J Med 1991; 90: 402-4
80. 80. Kohlhaw K, Wonigeit K, Frei U, et al. Effect of the calcium channel blocker diltiazem on cyclosporine A blood levels and dose requirements. Transplant Proc 1988; 20: 572-4
81. 81. Shennib H, Auger JL. Diltiazem improves cyclosporine dosage in cystic fibrosis lung transplant recipients. J Heart Lung Transplant 1994; 13: 292-6
82. 82. Sketris TS, Methot ME, Nichol D, et al. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother 1994; 28: 1227-31
83. 83. Wagner K, Philipp TH, Heinemeyer G, et al. Interaction of cyclosporin and calcium antagonists. Transplant Proc 1989; 21: 1453-6
84. 84. Jones TE, Morris RG, Mathew TH. Diltiazem-cyclosporin pharmacokinetic interaction: dose-response relationship. Br J Clin Pharmacol 1997; 44: 499-504
85. 85. Jones TE, Morris RG. Diltizem does not always increase blood cyclosporin concentration. Br J Clin Pharmacol 1996; 42: 642-4
86. 86. Schroeder J, Gao S-Z, Alderman E, et al. A preliminary study of diltiazem in the prevention of coronary artery disease. N Engl J Med 1993; 238: 164-70
87. 87. McMillen MA, Lewis T, Jaffe BM, et al. Verapamil inhibition of lymphocyte proliferation and function in vitro. J Surg Res 1985; 39: 76-80
88. 88. McMillen MA, Baumgarten WK, Schaefer HC, et al. Potentiation of cyclosporine by verapamil in vitro. Transplantation 1995; 40: 444-6
89. 89. Angermann CE, Spes CH, Anthuber M, et al. Verapamil increases cyclosporin-A trough levels in cardiac transplant recipients [abstract]. J Am Coll Cardiol 1988; 11: 206A
90. 90. Peterson JC, Brannigan J, Pickard T, et al. Cyclosporine-verapamil interaction. Kidney Int 1988; 33: 449-50
91. 91. Dawidson I, Rooth P, Lu C, et al. Verapamil improves the outcome after cadaver renal transplantation. J Am Soc Nephrol 1991; 2: 983-90
92. 92. Tjia JF, Back DJ, Breckenridge AM. Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes. Br J Clin Pharmacol 1989; 28: 362-5
93. 93. Bourbigot B, Guiserix J, Airiau J, et al. Nicardipine increases cyclosporin blood levels [letter]. Lancet 1986; 1: 1447
94. 94. Kessler M, Renoult E, Jonon B, et al. Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients [letter]. Eur J Clin Pharmacol 1989; 36: 637-8
95. 95. Cantarovich M, Hiesse C, Lockiec F, et al. Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients. Clin Nephrol 1987; 28: 190-3
96. 96. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63-79
97. 97. Fabre I, Fabre G, Maurel P, et al. Metabolism of cyclosporin A. III: interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions. Drug Metab Dispos 1988; 16: 296-301
98. 98. Henricsson S, Lindholm A. Inhibition of cyclosporine metabolism by other drugs in vitro. Transplant Proc 1988; 20: 569-71
99. 99. Kohan DE. Possible interaction between cyclosporine and erythromycin [letter]. N Engl J Med 1986; 314: 448
100. 100. Ptachcinski RJ, Carpenter BJ, Burckart GJ, et al. Effect of erythromycin on cyclosporine levels [letter]. N Engl J Med 1985; 313: 1416-7
101. 101. Gonwa TA, Nghiem DD, Schulak JA, et al. Erythromycin and cyclosporine. Transplantation 1986; 41: 797-9
102. 102. Wadhwa NK, Schroeder TJ, O'Flaherty E, et al. Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient. Ther Drug Monit 1987; 9: 123-5
103. 103. Jensen CWB, Flechner SM, Van Buren CT, et al. Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. Transplantation 1987; 43: 263-70
104. 104. Kreft-Jais C, Billaud EM, Gaudry C, et al. Effect of josamycin on plasma cyclosporine levels. Eur J Clin Pharmacol 1987; 32: 327-8
105. 105. Torregrosa JV, Campistol JM, Franco A, et al. Interaction of josamycin with cyclosporine A. Nephron 1993; 65: 476-7
106. 106. Gersema LM, Porter CB, Russell EH. Suspected drug interaction between cyclosporine and clarithromycin. J Heart Lung Transplant 1994; 13: 343-5
107. 107. Burke MD, Omar G, Thomson AW, et al. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. Transplantation 1990; 50: 901-2
108. 108. Pichard L, Fabre I, Fabre G, et al. Cyclosporine A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporine Aoxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606
109. 109. Adrianus AMJ, Hollander MD, Jeroaen van Rooij MD, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995; 57: 318-24
110. 110. Yee GC, Stanley DL, Pessa, et al. Effect of grapefruit juice on blood cyclosporine concentration. Lancet 1995; 345: 955-6
111. 111. Brunner LJ, Munar MY, Vallian J, et al. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy 1998; 18: 23-9
112. 112. Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33: 103-21
113. 113. Rouseff RL, Martin SF, Youtsey O. Quantitative survey of narirutin, naringin, hesperiden and neohesperidin in citrus. J Agric Food Chem 1987; 35: 1027-30
114. 114. Didlake RH, Dreyfus K, Kerman RH, et al. Patient non-compliance: a major cause of late graft failure in cyclosporine-treated renal patients. Transplant Proc 1988; 20: 63-9
115. 115. Gaston R, Hudson S, Ward M, et al. The relationship between graft loss and noncompliance [abstract]. Presented at the XVII World Congress of The Transplantation Society; 1998 May 10-13, Chicago
116. 116. Kiley DJ, Lam CS, Pollak R. A study of treatment compliance following kidney transplantation. Transplantation 1993; 55: 51-6
117. 117. Murphy J, Coster G. Issues in patient compliance. Drugs 1997; 54: 797-800
118. 118. Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric H and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114: 755-7
119. 2-receptor antagonist in a patient on ketoconazole. Transplantation 1994; 57 (6): 889-92
120. 120. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112
121. 121. Monahan BP, Ferguson CL, Killeavy ES, et al. Torsdes de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-90
122. 122. Oberg K, Bauman JL. QT interval prolongation and torsades de pointes due to erythromycin lactobionate. Pharmacotherapy 1995; 15: 687-92
123. 123. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16: 366-85
124. 124. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. Clin Pharmacol Ther 1989; 45: 366-72
125. 125. Gillum JG, Isreal DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450-82
126. 126. Cooke CE. Nontherapeutic cyclosporine levels: sustained-release diltiazem products are NOT the same. Transplantation 1994; 57: 1687-8
127. 127. Jones TE, Morris RG, Mathew TH. Formulation of diltiazem affects cyclosporine-sparing activity. Eur J Clin Pharmacol 1997; 52: 55-8
128. 128. Moore LW, Alloway RR, Acchiardo SR, et al. Clinical observations of metabolic changes occurring in renal transplant recipients receiving ketoconazole. Transplantation 1996; 61: 537-41